Currently, the most commonly used treatments to mitigate severe CRS include tocilizumab, an antagonist of the IL-6 receptor, and siltuximab, an antibody against IL-6, with great efficacy in controlling the major complications [15]. This evidence concerns the gene IL6 and congenital rubella syndrome.